OncoMatch/Clinical Trials/NCT05272293

Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML

Is NCT05272293 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies NK cell infusions for acute myeloid leukemia.

Phase 1/2RecruitingBelarusian Research Center for Pediatric Oncology, Hematology and ImmunologyNCT05272293Data as of May 2026

Treatment: NK cell infusions — The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Lab requirements

Liver function

SGOT or SCPT >=5x upper limit of normal for age [excluded]

severe hepatic dysfunction: SGOT or SCPT >=5x upper limit of normal for age

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify